-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

896 Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19

Program: Oral and Poster Abstracts
Session: 332. Anticoagulation and Antithrombotic Therapy: Poster I
Hematology Disease Topics & Pathways:
Coronaviruses, SARS-CoV-2/COVID-19, Adult, Study Population, Clinically relevant
Saturday, December 5, 2020, 7:00 AM-3:30 PM

Camille Simard, MD1*, Maral Koolian, MD, MSc, FRCPC2*, Diana Escobar, MD3*, Mark Blostein, MD FRCPC4*, Jed Lipes, MD, FRCPC5*, Adelina Teona Avram, MD1*, Ryan Kerzner, B Pharm, MSc6*, Helen Mantzanis, B Pharm, MSc6*, Mateo Porres Aguilar, MD1* and Vicky Tagalakis, MD, FRCPC7

1McGill University, Montreal, QC, Canada
2General Internal Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada
3McGill University, Monteal, QC, Canada
4Division of Hematology, Jewish General Hospital, McGill University, Montreal, QC, Canada
5Critical Care Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada
6Department of Pharmacy, Jewish General Hospital, Montreal, QC, Canada
7Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, QC, Canada


Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), a virus strain that appeared in Wuhan China in December 2019, that has since spread to become pandemic. An increased risk of venous and arterial thromboembolism has been consistently reported in critically ill patients with COVID-19 in several countries. The mechanism is thought to be multifactorial, largely mediated by the interplay between inflammation and the coagulation system, or thromboinflammation. We aim to report the risk of thrombosis in a Canadian patient population admitted to the intensive care unit (ICU) with COVID-19.


We conducted a retrospective cohort study of all consecutive patients with COVID-19 admitted to the ICU between March 1st, 2020 and May 10th, 2020 at the Jewish General Hospital (JGH) in Montreal, Canada. The JGH is a tertiary care centre in Montreal, the epicenter of the COVID-19 pandemic in Canada, and the JGH was the first designated hospitalization centre in Montreal for COVID-19 patients. Patients were followed from date of ICU admission to the earliest of the following: objectively confirmed venous or arterial thrombosis; discharge from hospital; death; or study end date (May 24th, 2020). We determined risk of venous (pulmonary embolism (PE) and deep vein thrombosis (DVT)) and arterial (myocardial infarction, cerebrovascular accident, arterial limb ischemia, and mesenteric ischemia) thrombotic events.


During the study period, a total of 90 patients admitted to the ICU with COVID-19 were included. The median age was 66 years (standard deviation (SD) 13.8), and 41.1% of patients were female. The median body mass index was 30 kg/m2(SD 5.1), and 64% of patients were mechanically ventilated and 10.1% received continuous renal replacement therapy. The median duration of follow-up was 17.1 days (SD 13.4). In all, 98.9% of patients were prescribed anticoagulation, among whom 78.2% were on a prophylaxis dose, 15.0% intermediate dose, and 6.9% therapeutic dose. In all, 11 (12.2%) patients developed a thrombotic complication among whom 9 patients had objectively diagnosed pulmonary embolism (PE) and 2 patients had an arterial thromboembolism. Both arterial events were cerebrovascular accidents. All PE episodes involved segmental arteries. One PE was incidental, and 3 patients had a concomitant diagnosis of DVT. Overall, death was observed in 16.7% of cohort patients and 12.2% of patients were still admitted to hospital at study end date.


In this first Canadian study of critically ill patients with COVID-19, we found a 12.2% risk of thrombotic complications despite almost 100% use of anticoagulation primarily with standard prophylaxis dosing. This risk is considerably lower than most reported estimates to date from critical care COVID-19 cohorts in Europe, China and the United States. Our results fuel the ongoing discussion of optimal dose of anticoagulation in these patients.

Disclosures: No relevant conflicts of interest to declare.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH